Bladder Cancer Surgery

Medifocus Guidebook on: Bladder Cancer

The MediFocus Guidebook on Bladder Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Bladder Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Bladder Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your cr

List Price: $ 24.95

Price:

Legal Help Available as More Actos Patients Discover Bladder Cancer Link

ActosCancer.com – Helping those affected by the side effects of Actos

Orlando, FL (PRWEB) November 17, 2011

Although the FDA only months ago issued a warning about the serious risks for bladder cancer associated with the diabetes drug Actos, the response from patients affected by the drug has been shocking.

Thousands of people diagnosed with bladder cancer after taking Actos have sought help in determining their legal rights against the maker of the drug, Takeda Pharmaceuticals.

On August 31, 2011, lawyers representing Nevada plaintiffs Glen and Nina Weant filed a motion with the U.S. Judicial Panel on Multidistrict Litigation (JPML) in Case NYE/1:11-cv-04502 asking that all federal Actos lawsuits be consolidated in an MDL court in the U.S. District Court for the Southern District of Illinois before Judge Murphy.

According to the motion, more than 12 lawsuits in 8 different federal district courts throughout the United States have been filed by patients who developed bladder cancer after taking Actos. The US Judicial Panel on Multidistrict Litigation has scheduled a hearing for December 1, 2011 to decide whether Actos lawsuits will be consolidated into an MDL.

A June 9, 2011 article in Bloomberg identified Actos as the leading diabetes treatment in the world, likely taken by millions of people. Sales of the drug were bolstered after studies in 2007 linked competitor Avandia to heart attacks and cardiovascular death.

On June 15, 2011, the U.S. FDA issued a warning that patients taking Actos for periods longer than one year could face an increased risk of developing actos bladder cancer.

The warning was based on an interim review of data from an ongoing 10-year study ordered by the FDA as well as a study by the French Medicines Agency. The French study tracked 155,000 patients taking the drug over four years, compared with 1.3 million diabetics not on the drug.

After a finding by the French study that those taking Actos for more than one year could face up to a 40% increase in the occurrence of bladder cancer, authorities in France and Germany halted use of the drug. The European Medicines Agency and FDA have issued strong warnings, but have not yet ordered a stop in sales.

According to the FDA, bladder cancer normally affects only 20 people out of 100,000. The National Cancer Institute claims there have been 69,250 new cases so far in 2011 with 14,990 deaths. However, the disease is considered highly treatable as the symptoms allow for early detection.

Actos was approved by the FDA in 1999 for the treatment of type II diabetes. According to the June 9, 2011 Bloomberg article, Japanese drug maker Takeda Pharmaceuticals earned $ 4.8 billion last year from sales of Actos alone.

Treatment of bladder cancer can require targeted chemotherapy as well as surgery to remove tumors or the entire bladder. Patients can face pain, long term disruption of bodily functions like urination and sexual ability, or even death.

Due to the extensive treatment, loss of function and long term medical monitoring required, damages for Actos bladder cancer could reach into the millions of dollars. Since there is a time limit on how long you have to take action, it is important for anyone affected to learn their legal options as soon as possible.

As with any highly-specialized case, an actos lawsuit is a very complex legal matter which could require extensive investigation and years of preparation. Before selecting a lawyer for help, make sure they have experience fighting large drug companies.

ActosCancer.com contains information on Actos, the research and side effects linked to the drug, as well as symptoms and treatment options for bladder cancer and how to find a lawyer who can help you recover.

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Sweet Sunnah Cinnamon Honey and Black Seed

• HEART DISEASES, INSECT BITES, ARTHRITIS, HAIR LOSS, BLADDER INFECTIONS
• COLDS, INFERTILITY, UPSET STOMACH, GAS, IMMUNE SYSTEM, INDIGESTION
• SKIN INFECTIONS, CANCER, FATIGUE, BAD BREATH, HEARING LOSS
• TOOTHACHE, CHOLESTEROL
• INFLUENZA, PIMPLES

Cinnamon Honey & Black Seed
Cinnamon Honey & Black Seed is a healthy and delicious whole food blend of cinnamon, raw honey and black seed. Cinnamon is well known as one of nature’s most powerful antioxidants. Our raw honey is 100% pure and natural from healthy beehives. This true raw honey provides the highest possible levels of liver enzymes, vitamins, minerals and antioxidant agents that functional as whole food .Enjoy the delightful taste of cinnamon honey on breads, bagels, biscuits or in yo

List Price: $ 13.00

Price:

Bladder Cancer: Diagnosis, Therapeutics, and Management (Current Clinical Urology)

In Bladder Cancer: Moving the Field Forward, Cheryl Lee, David Wood, and a panel of leading authorities and researchers provide a comprehensive review of the related literature, while providing insights into the obstacles of improved survival and discuss methods to advance the field of Bladder Cancer care. Their work aims to spur innovative thoughts and approaches to common problems in the management of early stage and advanced disease. The book discusses at length the state of bladder cancer st

List Price: $ 149.00

Price:

Kidney and Bladder Problems

• Includes clearly written, 15-chapter e-book
• Covers symptoms, treatments, and other related issues
• Features adjustable font type, size, and color

List Price: $ 4.99

Price:

Tena Serenity for Men, Discreet Bladder Protection, 48-Count Package

• Advanced leak protection
• Odasorb plus is works to control odors
• Soft cotton material for comfort all the time
• Good fit moves with you so you stay secure
• Secure protection- no leaking

Designed Especially for Men OdaSorb Plus to help control odors A simple & efficient solution for post-prostate surgery incontinence place OdaSorb Plus pH-balanced control odors Single Wrapped discreet portability Latex Free Dry Fast Core Sanitary Pads.

List Price: $ 25.41

Price:

Invasive Bladder Cancer

Invasive bladder tumors affect the muscle wall, and have a propensity to metastasize and spread to other areas of the body, and are more likely to be fatal. This book presents state-of-the-art diagnoses and treatments available for bladder cancer that has metastasised into the body. A thorough review of current practice is presented in a full color volume with more than 40 tables and 50 illustrations. The book offers a comprehensive review of the subject, covering epidemiology, screening, diagno

List Price: $ 119.00

Price:

Plainview, NY (PRWEB) October 7, 2009

More than 70,000 people in the United States will be diagnosed with new cases of bladder cancer in 2009, according to the National Cancer Institute. It’s the fourth most common type of cancer in men and the eighth most common in women, leading to roughly 14,000 deaths a year.

But today, researchers are fine-tuning a simple urine test that can detect bladder cancer up to six months before other methods, with up to 95 percent accuracy. It may replace invasive procedures such as a cystoscopy – in which a tube is snaked into the bladder – or a biopsy.

The test, called UroVysion,TM requires only a urine sample to detect genetic changes in cells from the bladder isolated from the urine, a key indicator of bladder cancer.

This advanced, non-invasive test will be used both to diagnose and monitor bladder cancer, says Dr. Shashi Pawar, an authority on genetics at Acupath Laboratories in Plainview, NY, who works with pathologists specializing in uropathology, the science of diagnosing illnesses within the urinary tract.

The test has the potential to make testing easier for the patient and doctor, enabling earlier detection of bladder cancer and saving lives.

Says Dr. Pawar, “Researchers believe the new test, from Abbott Labs, will help increase early detection rates for bladder cancer, which is frequently diagnosed in its later stages, making it more difficult to treat.”

Today, when bladder cancer is suspected, a physician may order a combination of diagnostic exams including laboratory urine tests; a PET or CT scan; a cystoscopy, and/or a surgical biopsy. UroVysion would allow pathologists to examine a urine sample for specific genes and genetic activity related to bladder cancer.

“Any time you make testing easier and less invasive, and can detect cancer earlier, the patient benefits,” says Pawar.

Bladder cancer symptoms include:

blood in the urine
pain during urination
frequent urination, or
frequently feeling the need to urinate without actually voiding.

Who’s at risk?

According to the American Cancer Society, men are three times more likely than women to develop bladder cancer. Since men are often less likely to seek medical attention when a symptom first arises because of apprehension about invasive tests, Pawar believes UroVysion may help encourage more early-stage patients to undergo testing sooner rather than later.

The precise causes of bladder cancer so far have eluded experts. Many believe that both genetic and environmental factors come into play. Risk factors include:

age — people under 40 rarely develop the disease
smoking — smokers are more than twice as likely to suffer from bladder cancer as nonsmokers, notes the American Cancer Society. Smoking can also be blamed for close to half of bladder cancer deaths
race — whites have the highest bladder cancer rates; Asians the lowest
family or personal history — people with family members who’ve had bladder cancer are at increased risk. Recurrence is also common among those who’ve had the disease, and
being a man.

Studies have also found that people who have been infected with parasites common in the tropics, or have been treated with the drugs cyclophosphamide or arsenic, are also at increased risk. Certain industrial chemicals often used in the dye industry — aromatic amines, such as benzidine and beta-naphthylamine — have also been linked to the disease.

About Acupath: Acupath is a leader in providing physicians and patients with accurate and innovative pathologic, molecular and cytogenetic analyses. It has a national reputation for offering the latest advances in uropathology and related technologies, and is accredited by the Joint Commission and College of American Pathologists, among other national organizations.

About Dr. Pawar: Shashi Pawar, Ph.D, FACMG, is the director of genetics at Acupath Laboratories Inc. (www.acupath.com). With more than 20 years of varied experience in molecular genetics and molecular pathology, Dr. Pawar is American board of Medical Genetics-certified in both clinical cytogenetics and clinical molecular genetics. Prior to joining Acupath, Dr. Pawar was the VP of technical development for Genova Diagnostics. She holds a fellows title with the American Board of Medical Genetics and is a member of the Association of Molecular Pathology. In addition, she has been published in the Journal of Biological Chemistry and the Proceedings of National Academy of Sciences, among others. She earned her Ph.D. in biochemistry at the City University of New York.

Conclusions:
Our study has demonstrated that the modeling of data in time and space has additional benefits over a purely spatial analysis. In addition to highlighting the areas with high and low relative risks, this model also allows the simultaneous study of persistency of spatial patterns over time and detection of `unusual’ time trends that may warrant further investigation. (Source: International Journal of Health Geographics)

MedWorm: Bladder Cancer

San Jose, California (PRWEB) February 22, 2010

Among all the known forms of cancer, bladder cancer is the seventh most common form of cancer that affects people worldwide. Bladder cancer places a significant risk of mortality and morbidity both on patients and the society. The risk of acquiring bladder cancer is high among smokers, aging population, workers at chemical industry, and among people with urinary tract infections. Individuals with a family history of bladder cancer are also more likely to inherit the disease. Patients primarily suffer from bladder cancer in their old ages and thus rise in the aging population group remains a key growth driver for bladder cancer therapeutics.

The United States and European markets dominate the world bladder cancer therapeutics market, as stated by the new market research report on bladder cancer therapeutics market. Bladder cancer is one of the leading types of cancer affecting Americans. Bladder cancer incidence in the US is increasing consistently since the late 1950s, and continues to increase with aging population. However, the incidence and prevalence of bladder cancer is highest in Europe, globally. Tobacco smoking, increased occupational exposure, and Schistosoma haematobium infection are major risk factors for bladder cancer in Europe.

Bladder cancer market presents immense commercial opportunities for the drug developers, specifically to address unmet needs in metastatic condition. Bacillus Calmette-Guerin (BCG) is the most widely used treatment for bladder cancer, and a ‘Gold Standard’ therapy for non-invasive cancer of the bladder. Newer drugs including Gemzar (Gemcitabine) also received approval for the treatment of superficial bladder cancer, in BCG refractory patients. Though there is no effective treatment for metastatic bladder cancer, more often systemic chemotherapy in combination with multi-agent regimes are used.

Key players profiled in the report include Allergan Inc., Allos Therapeutics Inc., Astellas Pharma Inc, Astrazeneca PLC, BioCancell Therapeutics Inc., Bioniche Life Sciences Inc., Celldex Therapeutics Inc., Cytavis BioPharma GmbH, Eli Lilly and Company, Endo Pharmaceuticals Holdings Inc., F. Hoffmann-La Roche Ltd, Halozyme Therapeutics Inc., Laboratoires Pierre Fabre SA, NatImmune A/S, Nippon Kayaku Co. Ltd, Oncogenex Pharmaceuticals Inc., PharmaMar S.A., Sanofi-Aventis, Spectrum Pharmaceuticals Inc., Telormedix SA, and Viventia Biotechnologies Inc, among others.

The report titled “Bladder Cancer Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, overview of bladder cancer treatment, product introductions/innovations, and recent industry activity. The study analyzes market data and analytics in terms of value sales for the United States, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit -

http://www.strategyr.com/Bladder_Cancer_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press(at)StrategyR(dot)com

Web Site http://www.StrategyR.com/

###